The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer

Gefitinib is currently the preferred treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutation. However, some patients gradually develop acquired resistance after receiving treatment. In addition to secondary T790M mutation, the remain...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncol Rep
Egile Nagusiak: Du, Wenwen, Sun, Lin, Liu, Ting, Zhu, Jianjie, Zeng, Yuanyuan, Zhang, Yang, Wang, Xueting, Liu, Zeyi, Huang, Jian-An
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2020
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7251657/
https://ncbi.nlm.nih.gov/pubmed/32319651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2020.7579
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak